Med24
metabolic-therapy 18. 10. 2026 • 2 min read • HIV medicine (PubMed)

Changes in cardiometabolic biomarkers 1 year after direct acting antiviral therapy for hepatitis C virus co-infection among people with HIV.

OBJECTIVES: Among people with HIV with hepatitis C virus (HCV) co-infection, we examined differences in haemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score at 12-months following direct acting...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

This study examined changes in cardiometabolic biomarkers one year after direct acting antiviral therapy for hepatitis C virus co-infection among people with HIV. The research compared individuals with HIV who initiated direct acting antiviral (DAA) therapy with those who did not, focusing on haemoglobin A1c (HbA1c), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL) and atherosclerotic cardiovascular disease (ASCVD) risk score. The study included people with HIV age ≥ 18 years, on antiretroviral therapy, from the NA-ACCORD and Mass General Brigham HIV cohorts. Individuals with detectable plasma HCV RNA were identified as having HCV co-infection.

Multivariable linear regression models were used to estimate HbA1c, TC, and ASCVD risk score at 12-months, comparing DAA initiators to non-initiators. The analysis involved 2374 individuals for HbA1c, 3418 for TC, and 488 for ASCVD risk score.

Results indicated no significant difference in the mean HbA1c at 12-months between DAA initiators and non-initiators. However, the mean TC was 13 mg/dL higher in DAA initiators, primarily due to increases in LDL. There was no significant difference in the mean ASCVD risk score at 12-months when comparing DAA initiators with those who did not initiate DAAs.

Sponsored content

The study concluded that people with HIV with HCV who initiated DAA demonstrated no statistically significant difference in HbA1c or ASCVD risk score at 12-months compared to HIV/HCV co-infected persons who did no initiate DAA. TC and LDL levels increased 12 months following DAA treatment.

Original Scientific Source
HIV medicine (PubMed)
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.
metabolic-therapy

Nanotechnology-Driven 18F-FDG Imaging to Understand the Change in Insulin Sensitivity: Current Evidence, Methodological Gaps, and Translational Challenges.

Insulin resistance is an important metabolic derangement contributing to the pathogenesis of type 2 diabetes, obesity, metabolic syndrome, and other chronic diseases, underlining the requirement for techniques that enable in vivo analysis of tissue-specific glucose metabolism. 18F-fluorodeoxyglucose positron emission...

10. 11. 2026 Read article →
Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.
metabolic-therapy

Cardiometabolic Abnormalities among Normal-Weight Adults: Prevalence and Associated Sociodemographic and Lifestyle Factors in a Large Spanish Cohort.

BACKGROUND: Although body mass index (BMI) is widely used to assess obesity-related health risks, it may fail to detect individuals with normal weight who present with significant cardiometabolic abnormalities. This phenotype, often overlooked in clinical practice, is associated with increased risk of cardiovascular...

30. 10. 2026 Read article →
Advertisement